LAS VEGAS — In this video, Ashkan M. Abbey, MD, FASRS, FAAO, of Texas Retina Associates, discusses his presentation at Clinical Trials at the Summit on the use of EyePoint’s Duravyu in neovascular age-related macular degeneration.
“We know that there is a reduction in treatment burden with maintenance of good vision and also anatomical control in the phase 2 trial, and now we hope to see the same results in the phase 3 prior to FDA approval,” Abbey told Healio.